JPRN-jRCTs041200028招募中2 期
agoya University Pancreatic Tumor Board trial 07 - NUPAT-07
Kodera Yasuhiro0 个研究点目标入组 50 人开始时间: 2020年7月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1.Borderline resectable pancreatic cancer
- •2.Age 20=< and =<79
- •3.Performance status 0-1
排除标准
- •1.distant metastasis
- •2.severe drug allergy
- •3.viable multiple primary cancer
- •4.gastrointestinal invasion
- •5.apparent infectious status
- •6.history of abdominal radiotherapy
- •7.pregnant or breastfeeding female
研究者
相似试验
招募中
2 期
agoya University Pancreatic Tumor Board trial 08ocally advanced pancreatic cancerJPRN-jRCTs041200054Kodera Yasuhiro50
进行中（未招募）
不适用
A trial comparing the current standard treatment (gemcitabine) to the experimental, combined treatments of gemcitabine plus capecitabine.Resectable pancreatic or peri-ampullary cancersMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-GBThe University of Liverpool1,396
进行中（未招募）
1 期
Comparing Gemcetabine and Capecitabine versus Gemcitabine monotherapy in chemotherapy for pancreatic cancerResectable pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-DEThe University of Liverpool1,068
进行中（未招募）
1 期
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableSystem Organ Class: 100000004864EUCTR2007-004299-38-SEThe University of Liverpool1,080
进行中（未招募）
不适用
European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. - ESPAC-4Resectable pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033602Term: Pancreatic adenocarcinoma resectableEUCTR2007-004299-38-FIThe University of Liverpool1,080